- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01239355
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the median progression-free survival in patients with advanced hepatocellular carcinoma treated with MK-2206 after failure of one prior line of anti-angiogenic therapy.
SECONDARY OBJECTIVES:
I. Evaluate the objective response rate (CR + PR). II. Evaluate the median overall survival. III. Evaluate the tolerability and toxicity profile of MK-2206 in this patient population.
IV. Explore, in a preliminary fashion, potential molecular predictors of efficacy.
OUTLINE:
Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 4 weeks and then every 3-6 months thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211-1850
- Tower Cancer Research Foundation
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
Los Angeles, California, United States, 90033
- USC Norris Comprehensive Cancer Center
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Evanston, Illinois, United States, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Harvey, Illinois, United States, 60426
- Ingalls Memorial Hospital
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates Limited
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Peoria, Illinois, United States, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, United States, 62702
- Southern Illinois University
-
Springfield, Illinois, United States, 62702
- Central Illinois Hematology Oncology Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
South Bend, Indiana, United States, 46628
- Northern Indiana Cancer Research Consortium
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland/Greenebaum Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Saint Joseph, Michigan, United States, 49085
- Oncology Care Associates PLLC
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Saint John's Mercy Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Unresectable or metastatic HCC for which standard curative measures do not exist
The diagnosis of hepatocellular carcinoma should be based on at least one of the following:
- The presence of one or more liver lesions, measuring >= 2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or hepatitis B or C infection
- The presence of liver lesion(s) with AFP >= 400
- Tissue confirmation in the absence of either or both of the above
- Tissue availability is desired and will be sought, but tissue availability is not mandated for accrual to the study
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension, and that has not been the target of local or regional therapy including transarterial chemoembolization, intra-arterial chemotherapy, ethanol, or RFA ablation
- One prior line of systemic anti-angiogenic therapy is required; this type of therapy includes, but is not restricted to, sorafenib, bevacizumab, sunitinib, or brivanib given as single agents or in combination with other agents
- No clinically evident ascites (minimal, medically controlled ascites detectable on imaging studies only is allowed)
- No Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with more than 7 points
- No fibrolamellar carcinoma or any mixed variants of HCC with dominant fibrolamellar histology
- Patients with known brain metastases should be excluded from this clinical trial
- ECOG 0-1
- Life expectancy of greater than 3 months
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count > 1,000 mcL
- Platelets >= 70,000/mcL
- Total bilirubin =< 1.5 institutional upper limit of normal
- AST (SGOT)/ALT (SGPT) < 5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min
- Serum albumin >= 2.8 g/dL
- Not pregnant or nursing
- Fertile patients must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
- Must agree to collection of correlative blood samples during the study
- No patients unable to swallow pills or diagnosed with a gastrointestinal disorder that is likely to interfere with the absorption of MK-2206 or with the patient's ability to take regular oral medication
- Patients with hyperglycemia should be well controlled on oral agents before the patient enters the trial
- Patients with HgbA1C levels >= 8% or fasting blood glucose >= 150 mg/dL are not eligible for this study
- Baseline QTcF > 450 msec (male) or QTcF> 470 msec (female) will exclude patients from entry on study
Patients with hepatitis B infection, defined by a positive hepatitis B surface antigen test, should be on suppressive anti-viral therapy
- Only the following anti-viral therapies are allowed while a patient is on study: tenofovir disoproxil fumarate and entecavir
- Patients with hypothyroidism must be on a stable dose of thyroid replacement and be clinically euthyroid
No esophageal or gastric variceal bleeding within the last 6 months
- Patients with prior history of variceal bleeding must have had an upper endoscopy (EGD) with appropriate treatment of varices within 6 months prior to study entry
No uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study requirements
None of the following:
- Uncontrolled hypertension (systolic BP > 150 or diastolic BP > 100 on two occasions within two weeks of beginning therapy on this protocol)
- Myocardial infarction within 6 months
- NYHA class > II
- Clinically significant bradycardia related to underlying cardiac disease
- Clinically significant bundle branch block related to underlying cardiac disease
No patients with second primary cancer (except adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors including lymphomas without bone marrow involvement curatively treated with no evidence of disease for ≥ 5 years)
- The exception to this criterion is prostate cancer treated definitively with surgery and/or radiation with normal PSA and no clinical evidence of residual or recurrent prostate cancer
- HIV-positive patients on combination antiretroviral therapy are ineligible
- No history of allergic reactions attributed to compounds of similar chemical orbiologic composition to MK-2206 or other agents used in the study
- No medications that cause QTc interval prolongation
Any number of prior regional therapies with transarterial chemoembolization, intra-arterial chemotherapy, or ablative therapy is allowed
- No more than 1 prior line of systemic therapy for advanced and/or unresectable disease
No patients who have had anti-angiogenic therapy, chemotherapy, radiotherapy or regional therapy (such as transarterial chemoembolization, intra-arterial chemotherapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Localized radiation for palliation (i.e., bony metastasis, etc.) given for < 3 days is allowed before therapy and is not subject to the 4-week waiting requirement
- Local ablative therapy such as radiofrequency ablation or cryotherapy must have been completed more than 2 weeks prior to study entry
- Patients may not be receiving any other investigational or non-investigational agents or therapies directed at treating their hepatocellular carcinoma
- Patients may not be receiving any other investigational agents for any condition
- Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (Akt inhibitor MK2206)
Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: Until disease progression or death, up to 26 months
|
Estimated using the product-limit method of Kaplan and Meier.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Until disease progression or death, up to 26 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response
Time Frame: Evaluated for response every 2 cycles (8 weeks) with confirmatory evaluation at least 4 weeks following initial documentation of objective response, up to 26 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR
|
Evaluated for response every 2 cycles (8 weeks) with confirmatory evaluation at least 4 weeks following initial documentation of objective response, up to 26 months
|
Overall Survival
Time Frame: Until death, up to 26 months
|
Survival will be estimated by the product-limit (Kaplan-Meier) estimator.
|
Until death, up to 26 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony El-Khoueiry, MD, University of Southern California, Norris
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2011-02549 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- P30CA033572 (U.S. NIH Grant/Contract)
- N01CM00038 (U.S. NIH Grant/Contract)
- CDR0000688549
- CHNMC-PHII-105
- PHII-105 (OTHER: City of Hope Comprehensive Cancer Center)
- 8752 (OTHER: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Adult Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Adult Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage D Adult Hepatocellular Carcinoma | Localized Resectable Adult Liver... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
AstraZenecaIonis Pharmaceuticals, Inc.CompletedAdvanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma MetastaticKorea, Republic of, Taiwan, Hong Kong, Japan
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Adult Hepatocellular CarcinomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedAdvanced Adult Hepatocellular CarcinomaUnited States
-
Immunovative Therapies, Ltd.CompletedAdvanced Adult Hepatocellular CarcinomaThailand
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States